Tag Archives: largest

Cell Expansion Market: Ethical concerns regarding research in cell biology investigated in the latest research – WhaTech

The Global Cell Expansion Market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.

The Cell Expansion Market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.

Growth in this market is primarily driven by the increasing incidence of chronic diseases, government investments for cell-based research, growing focus on personalized medicine, increasing focus on R&D for cell-based therapies, and increasing GMP certifications for cell therapy production facilities.

The media segment accounted for the largest share of the consumables segment in the cell expansion market

Based on product type, consumables are segmented into media, reagents, sera, and disposables. The media segment accounted for the largest share of the consumables segment in the cell expansion market.

The large share of this segment can be attributed to its high requirement during the production of pharmaceutical products and rising R&D investments on cell-based therapies.

Download a PDF Brochure @ http://www.marketsandmarkets.com/pdfdown=194978883

Biotechnology & biopharmaceutical companies accounted for the fastest-growing end user segment of the cell expansion market

Based on end-users, the cell expansion industry market has been segmented into research institutes, biotechnology & biopharmaceutical companies, cell banks, and other end users (includes hospitals, diagnostic centers, and laboratories). In 2019, biotechnology & biopharmaceutical companies were the largest end-users in the cell expansion market, and the trend is the same throughout the forecast period.

North America accounted for the largest share of the cell expansion market

North America accounted for the largest share of the cell expansion industry market.

The large share of this segment can primarily be attributed to the rising incidence of cancer, increasing government funding, rising research activates on stem cell therapies, growing awareness regarding advanced treatment methods, increasing geriatric population, and the strong presence of industry players in the region.

Request a Sample Pages @ http://www.marketsandmarkets.com/request=194978883

Leading Companies

Thermo Fisher Scientific, Inc. (US), Danaher (US), Becton, Dickinson and Company (US), Lonza (Switzerland), Corning, Inc. (US), Merck KGaA (Germany), Sartorius Stedim Biotech (France), Getinge AB (Sweden) Terumo Corporation (Japan), and Miltenyi Biotec (Germany)

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more:
Cell Expansion Market: Ethical concerns regarding research in cell biology investigated in the latest research - WhaTech

Animal Genetics Market Forecast to 2027 – COVID-19 Impact and Global Analysis By Product, Genetic Material, and Services and Geography. -…

New York, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Animal Genetics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product, Genetic Material, and Services and Geography." - https://www.reportlinker.com/p06010023/?utm_source=GNW However, the market is likely to get impacted by the limited number of skilled professionals in veterinary research and stringent government regulations for animal genetics during the forecast period.

The branch of genetics that deals with the study of gene variation and inheritance in companion, domestic and wild animals is called as animal genetics.Animal genetics are used for genetic trait testing, DNA testing, and genetic disease treatment.

Animal genetics is one of the best mainstays of livestock development (alongside animal nutrition, animal health, and husbandry concerns such as housing). According to the Food and Agriculture Organization of the United Nations, it is a wide field, ranging from characterization to maintenance to genetic improvement, and involves activities at local, national, regional, and global scales.Increasing population and rapid urbanization across the world has resulted in growing preference for animal derived food products such as dairy products and meat that contain high protein.The demand for animal derived proteins and food products, which, in turn drives the growth of animal genetics market.

Growing focus on developing superior animal breeds using genetic engineering to obtain high reproduction rates for large-scale production of modified breeds is expected to drive animal genetics market during the forecast period.Based on product, the market is segmented into poultry, porcine, bovine, canine, and others.The porcine segment held the largest share of the market in 2019, whereas the same segment is anticipated to register the highest CAGR in the market during the forecast period.

Growth of this segment is attributed to rise in production of porcine and increase in pork consumption across the globe.Based on genetic material, the market is segmented into semen and embryo. The embryo segment held the largest share of the market in 2019, and the semen segment is anticipated to register the highest CAGR in the market during the forecast period.COVID-19 pandemic has become the most significant challenge across the world.This challenge would be frightening, especially in developing countries across the globe, as it may lead to reducing imports due to disruptions in global trade, which further increases the shortages of meat and dairy product supplies, resulting in a considerable price increase.

Asian countries such as China, South Korea, and India are severely affected due to COVID-19 outbreak.The World Health Organization, Food and Drug Administration, American Pet Products Association, American Veterinary Medical Cattle Health, and Welfare Group for Disease Control and Prevention are among the major primary and secondary sources referred for preparing this report.Read the full report: https://www.reportlinker.com/p06010023/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Go here to see the original:
Animal Genetics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product, Genetic Material, and Services and Geography. -...

AstraZeneca to buy Alexion in US$39b immunology deal – New Zealand Herald

Business

12 Dec, 2020 07:09 PM4 minutes to read

AstraZeneca has agreed to buy US biotechnology group Alexion in a US$39b deal. Photo / Kirsty Wigglesworth

Anglo-Swedish drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a US$39 billion ($55.02b) deal, marking the biggest agreement struck by a pharmaceutical company since the start of the Covid-19 pandemic.

The cash-and-stock takeover will deepen AstraZeneca's core focus on immunology, by bringing a pipeline of experimental drugs that target rare diseases as it races to develop a coronavirus vaccine.

For Alexion, the sale follows pressure from activist hedge fund Elliott Management, which in May demanded the company sell itself, citing management missteps.

The transaction announced on Saturday comes after months of speculation that AstraZeneca chief executive Pascal Soriot was hunting for a large target, seeking to take advantage of a soaring share price that has seen the UK drugmaker become one of the largest listed businesses on the FTSE 100.

The transaction values Alexion at US$175 per share, a 45 per cent premium to its closing price on Friday. Alexion shareholders will own about 15 per cent of the combined company.

Under the terms of the transaction, Alexion shareholders will receive US$60 in cash and 2.12 shares from AstraZeneca's US-listed entity for each share they hold.

The acquisition is the biggest transaction in pharmaceuticals since 2019, when AbbVie acquired Allergan for US$63b, and the largest deal to target a US company in any sector this year.

Alexion focuses on diseases that are caused by an uncontrolled activation of a part of the immune system known as the complement system that spurs antibodies' abilities to clear microbes and promotes inflammation. Alexion has a pipeline of 11 molecules that AstraZeneca will help to build on.

The UK-based company believes this approach can also be applied to more common diseases.

Soriot said Alexion would strengthen AstraZeneca's position in the US where it has been rebuilding its presence in recent years, notably in oncology. The benefits flowed both ways, he indicated. Alexion had only a limited foothold in emerging markets "and almost zero presence in China", both areas in which AstraZeneca is strong, allowing for more effective globalisation of Alexion's portfolio.

Soriot said talks began "a few months ago" and that AstraZeneca was not aware of rival bidders. "To our knowledge there was not a competitive process," he said.

Analysts at SVB Leerink said: "While we have long suggested that US$175 was the right range for an acquisition, in today's inflated market we believe investors could demand more from AstraZeneca, or another acquirer."

They added: "This is such a scarce and high-quality asset that in this instance, the final transaction price may need to reach US$200 to satisfy Alexion's shareholders, or to be based more in cash, rather than predominantly stock."

AstraZeneca is targeting US$500m in pre-tax synergies from the deal, which Soriot said would partly come from headcount reduction in general administrative functions. Alexion has about 3,000 employees, while AstraZeneca has about 70,000.

The companies said they expected the acquisition to close in the third quarter of next year.

"When you conclude that the combination is going to be good and is going to work well you do it when the opportunity arises," Soriot said when asked about the interplay of the coronavirus pandemic and the deal.

AstraZeneca became Oxford university's partner for the development of a vaccine for coronavirus earlier this year. It has pledged to sell it at cost during the pandemic, and at no profit to developing nations in perpetuity. It has no native vaccine business, focusing instead on R&D in such areas as oncology.

Peer reviewed data released this month showed a pooled average efficacy of 70 per cent, less than for vaccines made by competitors. Observers have questioned the data, though any one vaccine with efficacy greater than 50 per cent is still set to be approved by European and US regulators.

Soriot said he expected AstraZeneca to be able to file for regulatory approval for the vaccine in the US within six weeks and that approval for some jurisdictions was expected before the end of the year.

Evercore and Centerview Partners were lead financial advisers to AstraZeneca, while Ondra provided capital markets advice. Morgan Stanley, JPMorgan and Goldman Sachs will help AstraZeneca finance the deal. Freshfields was AstraZeneca's legal adviser. Bank of America advised Alexion and Wachtell provided legal advice.

Read more:
AstraZeneca to buy Alexion in US$39b immunology deal - New Zealand Herald

Inception Fertility Expands EMR Partnership with PracticeHwy | Texas | tylerpaper.com – Tyler Morning Telegraph

HOUSTON, Nov. 16, 2020 /PRNewswire/ --In its latest effort to enhance the patient experience, Inception Fertility (Inception), a family of comprehensive fertility practices and companies, announces today it has expanded its strategic partnership with PracticeHwy's electronic medical record (EMR) system, eIVF. The EMR system will be available to every practice within the Inception family of fertility providers nationwide including The Prelude Network (Prelude) and Pathways Fertility (Pathways). Prelude is the clinic network of Inception and is the fastest-growing network of fertility clinics in the country. Pathways provides couples and individuals the chance to build their families through affordable care backed by the latest technologies in assisted reproductive medicine.

The partnership delivers on Inception's mission to better streamline fertility care and combine it with its approach to provide compassionate, individualized fertility treatment that utilizes the latest science. "As the nation's largest provider of fertility services, we are excited to expand our collaboration with eIVF and continue our efforts in strengthening how we streamline patient care," says TJ Farnsworth, CEO and Founder of Inception. "By providing enhanced interoperability throughout the entire Prelude Network and Pathways Fertility, we elevate our commitment to delivering best-in-class standards in patient outcomes and experience."

In addition to Prelude and Pathways, Inception's growing network of national organizations includes MyEggBank, one of the largest frozen donor egg banks in North America; andBundl Fertility (Bundl), a multi-cycle fertility service bundling company.

"We are excited to leverage the experience, strength, and national reach of our Inception partnership as we continue to enhance eIVF's suite of offerings," says Jawid Rahimi, Chief Executive Officer at PracticeHwy. "With over 50% of cycles in the US managed on eIVF, we have the most evolved capabilities in the market and are proud to offer Inception practices a solution to maximize operational efficiency and patient care."

A pioneer in the fertility industry, eIVF has been utilized in over one million cycles at practices throughout the world and continues to trailblaze a path of innovation. Its robust approach to practice management includes streamlined scheduling tools, an intelligent fertility-based billing platform that drives financial outcomes as well as the patient experience, and the most comprehensive Embryology and Andrology solution available. This platform also offers revolutionary lab management and electronic witnessing system, and its powerful research portal provides 24/7 access to built-in strategic KPI reports to drive better results.

For Inception, it was crucial to find a partner that would be able to support their continued trajectory of growth. "With an ever-growing enterprise, it is important to not only find a partner to handle the needs of our 70 providers, but to also provide scalability as we continue to grow the Inception network," says Farnsworth.

About PracticeHwyPracticeHwy is an international leader in healthcare software that serves approximately 130 practices and clinics worldwide. In 2002, they launched eIVF, one of the first electronic medical record (EMR) platforms focused on Reproductive Endocrinology and Infertility (REI) practices. Since then, eIVF has been utilized on over a million cycles. Known for its pursuit of excellence in the fertility industry, PracticeHwy.com has seen trajectory growth throughout the years by continuously developing new software solutions that support all aspects of a fertility clinic's operations. http://www.eivf.org

About Inception Fertility Inception Fertility (Inception) is a family of fertility brands committed to helping patients build their own families. Built by patients for patients, Inception's purpose is to achieve the highest bar in experience, science and medicine to enhance each patient's experience and achieve better outcomes.

Through its growing family of national organizations which includesThe Prelude Network, the fastest-growing network of fertility clinics and largest provider of comprehensive fertility services in the U.S.;Pathways Fertility, clinics that provide affordable, individualized and high quality care;MyEggBank, one of the largest frozen donor egg banks in North America; andBundl Fertility (Bundl), a multi-cycle fertility service bundling program Inception is working to deliver on its promise to push the envelope of what is possible for exceeding patient expectations.

Media Contact:Mia HumphreysKrupp KommunicationsMHumphreys@kruppnyc.com239-297-6592

See the article here:
Inception Fertility Expands EMR Partnership with PracticeHwy | Texas | tylerpaper.com - Tyler Morning Telegraph

Live Cell Imaging Market worth $2.8 billion by 2025 – Exclusive Report by MarketsandMarkets – PRNewswire

CHICAGO, Oct. 29, 2020 /PRNewswire/ -- According to the new market research report "Live Cell Imaging Market by Product (Instruments, Consumables, Software, Services) Application (Cell Biology, Drug Discovery) Technology (Time-lapse Microscopy, FRET) End User (Contract Research Organization, Research Institutes) - Global Forecast to 2025", published by MarketsandMarkets, the global market size is projected to reach USD 2.8 billion by 2025 from USD 1.8 billion in 2020, at a CAGR of 8.8% during the forecast period.

Browse in-depth TOC on "Live Cell Imaging Market"

146 Tables 40 Figures 212 Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483

The growing adoption of high-content screening techniques in drug discovery, rising incidence of cancer, and the growth in funding for research are the major factors driving the growth of this market.

"The reagents segment is expected for the largest share of the live cell imaging market in 2019."

Based on type, the live cell imaging consumables market is segmented into reagents, media, assay kits, and other consumables (microplates, slides, Petri dishes, coverslips, and culture chambers). In 2019, the reagents segment accounted for the largest share of 36.1% of the consumables market. The large share of this segment can primarily be attributed to the growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields. With advancements in technologies, the demand for high-quality reagents in biomedical research and processing is on the rise. The increasing demand for high-quality reagents and their repeated use in live-cell imaging procedures are also factors driving the growth of this market.

By technology, the high-content screening (HCS) segment is expected to grow at the highest CAGR during the forecast period."

Based on technology, the live cell imaging market is segmented into fluorescence resonance energy transfer (FRET), time-lapse microscopy, fluorescence recovery after photobleaching (FRAP), high-content screening (HCS), and other technologies. High-content screening (HCS) segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the increasing studies on cell behavior and the need to correlate multiple events and markers with cell morphology.

Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=163914483

"North America to hold the largest regional market share in 2019."

North America is expected to account for the largest share of the live cell imaging market in 2019, followed by Europe. The large share of North America can be attributed to factors such as the availability of government funding for life science research, drug development regulations, advances in live-cell imaging techniques, growth in the biotechnology and pharmaceutical industries, and the rising incidence of cancer.

The prominent players in this live cell imaging market are Danaher Corporation (US), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer, Inc. (US), GE Healthcare (US), Bruker Corporation (US), Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), Oxford Instruments (UK), BioTek Instruments (US), Etaluma, Inc. (US), CytoSMART Technologies (Netherlands), NanoEnTek Inc. (Korea), Phase Focus Limited (UK), Tomocube, Inc. (South Korea), Phase Holographic Imaging PHI AB (Sweden), BD Biosciences (US), Sony Biotechnology, Inc. (US), Merck KGaA (Germany), KEYENCE Corporation (Japan), ibidi GmbH (Germany), Bio-Rad Laboratories (US), Logos Biosystems (South Korea), and Nanolive SA (Switzerland).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting

Get Special Pricing on Bundle Reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=163914483

Browse Related Reports:

Cell Culture Market by Product (Consumables (Media, FBS), Equipment (Bioreactor, Centrifuge, Incubator, Microscope, Autoclave)), Application (Stem Cell, Vaccines, Therapeutic proteins), End User (Pharma, Research Institutes) - Global Forecast to 2024

https://www.marketsandmarkets.com/Market-Reports/cell-culture-market-media-sera-reagents-559.html

Cell-based Assay Market by Product (Reagents, Microplates, Cell Lines, Assay Kits, Instruments, Services), Application (Drug Discovery, Research), End User (CROs, Biopharma Companies, Research Institutes), Geography - Global Forecast to 2024

https://www.marketsandmarkets.com/Market-Reports/cell-based-assays-market-119917269.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Aashish MehraMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [emailprotected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/live-cell-imaging-market.aspVisit Our Web Site: https://www.marketsandmarkets.comContent Source: https://www.marketsandmarkets.com/PressReleases/live-cell-imaging.asp

SOURCE MarketsandMarkets

See the article here:
Live Cell Imaging Market worth $2.8 billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire

Lyft is Tapping its Drivers to Collect Data for Improving its Self-Driving Vehicles and Build HD Maps – FutureCar

Author: Eric Walz

The robust software powering today's self-driving vehicles is not static, its continuously evolving and being refined using AI and machine-learning algorithms so autonomous vehicles (AVs) can better handle unexpected driving scenarios.

However, in order to do this, massive amounts of real-world data is needed to train AI-powered autonomous driving systems, so they can be improved over time. Ride-hailing company Lyft, is turning to its drivers for assistance in gathering all of this data. Turns out that simple dash cams used by Lyft's drivers are an ideal way to collect data while driving through urban areas.

Some drivers on Lyft's ride-hailing platform are using small, low-cost dash cameras to collect footage of intersections, bicyclists, pedestrians, as well as the behavior of other drivers while the Lyft driver is out and about picking up passengers.

By collecting the driver data, Lyft is helping to accelerate the development of autonomous driving technology as its highly valuable to improve the software and AI that powers the self-driving development vehicles.

Since Lyft's service its accessible to 95% of the U.S. population, it's one of the largest datasets in the world of real world driving scenarios.

The real-world data is used to train machine learning models so Lyft's engineering teams can better understand how human drivers behave in various traffic situations. For example, Lyft's data can be used to better predict how fast drivers travel on a particular stretch of road, or the probability that a human driver will enter an intersection when the traffic signal turns yellow.

The data can also be used to produce highly detailed 3D maps, which are an essential tool for self-driving vehicles to navigate with.

Using Driver Data to Improve HD Maps

Using rideshare data, Lyft was able to build city-scale 3D geometric maps using technology developed by Blue Vision Labs, an augmented reality software company acquired by Lyft in 2018.

High-definition maps contain much more detailed information compared with traditional maps. For instance, the maps used by self-driving vehicles contain the exact position of each lane and traffic light information of intersections, such as if an intersection has a traffic light that allows vehicles to make protected turn lefts. The HD maps even include elevation data and the location of street signs.

Lyft generates this information from its rideshare data by using a combination of 3D computer vision and machine learning to automatically identify traffic objects from the camera feed, such as other vehicles, pedestrians and road signs.

All of this information helps Lyft's engineers understand how drivers behave in risky situations, like a driver running a particular red light or failing to properly yield.

Lyft said it mapped thousands of miles using the wide geographic coverage of the vehicles on its ride-sharing network. Lyft continuously updates its maps from data collected from each trip. After it's collected, the data is immediately logged each time a ride is completed.

While mapping operations teams can build 3D maps for AVs, keeping them up-to-date is a challenge without continuously updated information. For example, a lane closure due to construction needs to be included in the 3D maps and pushed out to Lyft's autonomous vehicles for navigation. By using real data from driver's that traverse this area, Lyft can better train its AVs to better navigate through the hazard.

In addition to assisting Lyft to build 3D geometric maps, data rideshare network data helps the company to better understand human driving patterns. Using visual localization technology, Lyft is able to track the real-world trajectories that Lyft drivers follow when making turns or traveling in a lane with a greater level of accuracy.

This helps Lyft's self-driving vehicles to maintain the optimal location in their lane based on human driving patterns, so the software more closely mimics how drivers navigate urban road environments.

The data helps Lyft determine the optimum lane position for its AVs that more closely match how human drivers behave.

The data also helps Lyft's autonomous vehicles to better handle aggressive drivers and those who don't always obey road rules.

For example, if drivers are constantly being cut near a busy intersection where traffic merges, the data can be used to tune the software to anticipate this behavior and determine the appropriate deceleration profile, instead of having to slam on the brakes after being cut off by an aggressive driver.

This enables Lyfts's AVs to respond more safely in similar situations and behave more like a human driver, lessening the anxiety for passengers that will one day ride in Lyft's self-driving vehicles.

For developers of self-driving vehicles, building highly detailed maps and better understanding human driving behavior is critical. This data driven approach can help accelerate AV development, allowing developers to better address motion planning challenges of navigating in an urban environment.

By using this approach, Lyft is not just solely relying on previous AV trips or computer simulation simulation environments to determine how its vehicles should behave. Instead the company is leveraging real data from one of the largest ride-sharing networks in the world.

Lyft is not alone in its efforts. Waymo, which spun out of Google's self-driving car project, is also sharing its vehicle data with researchers.

In August 2019, Waymo released its "Waymo Open Dataset" for researchers and developers working on autonomous driving and other related mobility projects. Waymo says its dataset is the largest, richest, and most diverse self-driving dataset ever released for research purposes.

Like Lyft, the data was collected by a fleet of Waymo self-driving vehicles that traveled over 10 million miles in 25 different cities.

The dataset includes high-resolution sensor data covering a wide variety of environments, including dense urban areas and suburban streets. That data was also collected in a wide variety of real-world conditions, including day and night, bright sunlight and rain.

Waymo's own engineers use the same dataset to develop self-driving technology and innovative machine learning models and algorithms. With the release of Waymo's dataset, engineers outside of Waymo are getting access to the same data the Waymo's uses for the first time ever.

Original post:
Lyft is Tapping its Drivers to Collect Data for Improving its Self-Driving Vehicles and Build HD Maps - FutureCar

Add ear gene therapy company Akouos to the ever-growing list of IPOs amid Covid-19 – Endpoints News

For investors looking to cash in on a burgeoning ear therapy space, the latest biotech angling for a public debut could be music to their ears.

Fresh off a $105 million raise in March, ear gene therapy company Akouos is looking for another $100 million for a chance to dance on the Nasdaq well before its lead product enters the clinic.

Hearing aids and cochlear implants do address ear damage caused by genetics, noise, aging, or drugs, but nothing quite cures or indeed targets the biological underpinnings of hearing loss this is the gap Akouos and a handful of others in the space want to bridge.

I think some of the early efforts in the hearing space have been drawn to the largest affected populations where there happens to be less clarity on the underlying biology mechanism, chief Manny Simons said in a previous interview with Endpoints News. So were focusing our attention on forms of hearing loss that we feel are well-understood, well-characterized, where we can potentially address the underlying cause.

The companys lead experimental therapy AK-OTOF is engineered to treat hearing loss due to mutations in the gene that encodes otoferlin, a protein that enables the sensory cells to activate auditory neurons that carry electronically encoded acoustic information to the brain, which allows us to hear.Akouos plans to submit an application to take the drug into human studies next year, and generate early-stage data in 2022.

Simons, who founded the company in 2016, initially flirted with the idea of becoming a musician, growing up playing the piano and the trumpet. He met his wife at a glee club at Harvard. For his bachelors degree, he had the opportunity to essentially create his own course of study: to understand how the brain processes music, on the basis of imaging studies. That path led to the ear to decipher how sound is encoded into a neural impulse that can extend deep into the brain.

After getting his first taste of entrepreneurship in the prolific lab of drug delivery researcher Bob Langer, he got his biopharma training wheels off with stints at Third Rock backed-Warp Drive Bio and Voyager Therapeutics (neither of which were ear focused). But when he learned that AAV vectors with potential applications for the ear were being developed in a laboratory at Massachusetts Eye and Ear, Simons seized the opportunity to get a hearing-focused gene therapy company off the ground.

After securing a sweet $7.5 million in seed funding in 2018, Akouos scored $50 million in a Series A round in 2018, led by 5AM and New Enterprise Associates.

Akouos, akin to some others in the gene and cell therapy space, is investing heavily in manufacturing infrastructure having taken note that the complex manufacturing process for these kinds of therapies has become something of an Achilles heel in the field when it comes to adoption if the production apparatus is not up to scratch. For instance, the uptake of CAR-T therapies Novartis Kymriah and Gileads Yescarta underwhelmed initial expectations, despite their abundant promise. The uptake of Kymriah was plagued by manufacturing problems, and despite Novartis attempt to expand its capacity, sales have disappointed commercially, giving Yescarta an edge in the market.

Akouos is building its own infrastructure to manufacture vectors for its slate of experimental therapies, which also include genetic medicines for the most common forms of hearing loss, such as age-related and noise-induced hearing loss. The company is also planning on building a plant to process gene therapy batches to support activities through Phase I/II clinical trials for product candidates beyond AK-OTOF partner Lonza will help manufacture AK-OTOF while it is shepherded through clinical development.

The company plans to list on the Nasdaq under the symbol AKUS amid a broader rush of biopharma companies that are making their way to the public markets despite the disruption of Covid-19. Indeed, investor appetites have appeared seemingly insatiable given the raft of splashy IPOs in recent weeks, including a $424 million debut for a J&J-partnered Chinese biotech Legend Biotech, marking one of the largest public raises in biotech history.

Meanwhile, there are a host of rivals in the broader ear-focused space. Also in Boston, Akouos home, is Decibel Therapeutics, working on regeneration by targeting tiny hairs that grow in the inner ear to address congenital hearing loss or age-related balance disorders. Frequency Therapeutics has a mid-stage hair cell regeneration program using progenitor cells.

Across the Atlantic, UK-based Rinri Therapeutics is working on treating hearing loss by transplanting otic neural progenitor cells into the inner ear. Amsterdam-based Audion Therapeutics has a compound in-licensed from Eli Lilly, which is designed toturn on a chemical switch to produce new sensory hair cells from other cells in the inner ear to improve hearing.

Read the original here:
Add ear gene therapy company Akouos to the ever-growing list of IPOs amid Covid-19 - Endpoints News

CSL Behring and Seattle Children’s Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases – P&T Community

SEATTLE and KING of PRUSSIA, Pa., June 2, 2020 /PRNewswire/ --Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.

Initially, the alliance will focus on the development of treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome and X-linked Agammaglobulinemia. These are two of more than 400 identified primary immunodeficiency diseases in which a part of the body's immune system is missing or functions improperly.

"CSL Behring will collaborate with Seattle Children's experts to apply our novel gene therapy technology to their research pipeline, with an aim to address unmet needs for people living with certain rare primary immunodeficiency diseases," said Bill Mezzanotte, MD, Executive Vice President, Head of Research and Development for CSL Behring. "Expanding our gene therapy portfolio into an area of immunology well known to CSL exemplifies how we are strategically growing our capabilities in this strategic scientific platform and are collaborating with world class institutions to access innovation with the potential to vastly improve patients' lives."

"Stem cell gene therapies that correct the genetic abnormality driving a child's disease will transform the therapeutic options for children with Wiskott-Aldrich Syndrome, X-Linked Agammaglobulinemia and other immunodeficiency diseases,"said David J. Rawlings, MD, director of the Center for Immunity and Immunotherapies and division chief of immunology at Seattle Children's, and a professor of pediatrics and immunology at the University of Washington School of Medicine."The collaboration with CSL Behring supports our longstanding research programs for pediatric immunodeficiency diseases and will accelerate this research toward clinical trials, helping get these innovations to the children who need them."

CSL Behring researchers, working with researchers from Seattle Children's Research Institute, will investigate applying the proprietary platform technologies, Select+ and Cytegrity, to several pre-clinical gene therapy programs. These technologies, which have broad applications in ex vivo stem cell gene therapy, are designed to address some of the major challenges associated with the commercialization of stem cell therapy, including the ability to manufacture consistent, high-quality products, and to improve engraftment, efficacy and tolerability.

Wiskott-Aldrich Syndrome (WAS) has an estimated incidence between one and 10 cases per million males worldwide, according to the National Institutes of Health. WAS patients' immune systems function abnormally, making them susceptible to infections. They also experience eczema, autoimmunity and difficulty forming blood clots, leaving them vulnerable to life threatening bleeding complications. Today the only knowncurefor WAS is a stem cell transplant, if a suitable donor can be found.

X-linked Agammaglobulinemia (XLA) is another rare primary immunodeficiency in which patients have low levels of immunoglobulins (also known as antibodies), which are key proteins made by the immune system to help fight infections. Like WAS, XLA affects males almost exclusively, although females can be genetic carriers of the condition. While no cure exists for XLA, the goal of treatment is to boost the immune system by replacing missing antibodies and preventing or aggressively treating infections that occur, according to the Immune Deficiency Foundation.

About Seattle Children's

Seattle Children's mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children's Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children's hospitals in the country by U.S. News & World Report, Seattle Children's serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho the largest region of any children's hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children's Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children's Hospital and Research Foundation works with the Seattle Children's Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children's bold initiative It Starts With Yes: The Campaign for Seattle Children's to transform children's health for generations to come.

For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, and delivers its life-saving therapies to people in more than 70 countries. For more information, visit http://www.cslbehring.com and for inspiring stories about the promise of biotechnology, visit Vita http://www.cslbehring.com/Vita.

View original content to download multimedia:http://www.prnewswire.com/news-releases/csl-behring-and-seattle-childrens-research-institute-to-advance-gene-therapy-treatments-for-primary-immunodeficiency-diseases-301069305.html

SOURCE CSL Behring

The rest is here:
CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases - P&T Community

Immunai launches with $20M to map the human immune system – VatorNews

The company has already mapped out millions of immune cells and their functions

It hasn't been all that long since we unlocked the human genome, but the effect on healthcare has already been massive. It's even led to a whole new category, personalized medicine, that could very well totally overhaul healthcare we as know it by creating therapies specifically targeted to that specific person.

What if we could do the same thing for our immune system? That's the idea behindImmunai, a company thatlaunched out of stealth on Thursday with $20 million in seed fundingled byViola VenturesandTLV Partners.

The company, founded in December 2018 by ex-Harvard-MIT postdoc researcher Noam Solomon and ex-MIT and Palantir ML engineer Luis Voloch, usesartificial intelligence and machine learning algorithms to better understand the immune system so it can detect, diagnose, and treat disease.

"When I met Luis, I was a math postdoc at MIT and Luis was working to apply machine learning to biology. Together, we wanted to transfer learning methods with AI and define a comprehensive immunological knowledge base. We realized that almost 50 percent of melanoma patients were treated well with immunotherapy, but researchers could not transcend it to lesser-known cancer indications because theres no real database for cancer or immunity," Solomon told VatorNews.

"The main issue here is that all types of diseases, not just cancer, come back to the immune system and how it functions. And, without a comprehensive understanding of the immune system, we wont have highly targeted and effective drugs that actually improve our health."

What does is Immunai can extract over a terabyte of data from a single blood sample. Its database and machine learning algorithms can then be used to map incoming data to hundreds of cell types and states in order to create immune profiles by highlighting differentiated elements. Itsdatabase of immune profiles can be used for biomarker discovery and insight generation, identifying subtle changes in cell type and state-specific expression that can be used to distinguish them from normal expression.

The company has already mapped out millions of immune cells and their functions, building what it says is the largest proprietary data set in the world for clinical immunological data. It can analyze the evolution of disease, including cancer to autoimmune disorders to cardiovascular diseases.

"We combine single-cell biology with AI to provide pharma companies, hospitals, and clinics with a comprehensive understanding of the immune system to better detect, diagnose, and treat disease," said Solomon.

"We have an end-to-end vertically integrated platform on both the lab and computational side that allows us to analyze tens of thousands of genes to build the largest database for immunology to-date."

Right now, no other companies are doing exactly what Immunai is doing, he told me, though companies have been trying to understand the immune system for years. They, however, "have only been looking at two cells, PCR and TCR, and couldnt solve the prohibitive batch problem," while Immunai "can take the complexity of the immune system, simplify it and derive insights from it.

"Were disrupting legacy companies by analyzing 10,000x more data for each cell than they are," Solomon told me.

Immunai hasalready signed seven-figure deals with Fortune 100 pharmaceutical companies, and is helping them accelerate their clinical trials for drugs in the immunotherapy and cell therapy space. It has clinical partnerships with over 10 medical centers, as well as multiple commercial partnerships with cell therapy and checkpoint blockade with biopharma companies. It also has long-term partnerships with research institutions including Upenn, UCSF, Baylor, and others.

The new funding will be used, in part, to expand its team of scientists, engineers, and machine learning experts, which currently consists of 30 employees across New York City, Tel Aviv and San Francisco. It will also be used to build out the company's business functions and further develop its technology.

"The goal is to continue growing our database so that we can apply our learning from one disease to another," Solomon explained.

The company's ultimate mission, he told me, is to "make the biggest impact on healthcare with machine learning by giving researchers and clinicians a better understanding of the immune system."

"We believe this is an incredibly interesting and difficult problem to solve. Weve spent the last year perfecting our technology and building a team of experts across immunology and computer science, so were excited to have this opportunity to grow and make an impact on the next generation of drugs that are being developed.fc"

(Image source:immunai.com)

Read the rest here:
Immunai launches with $20M to map the human immune system - VatorNews

Memorial Neuroscience Institute Performs Its First Robotic Brain Surgery to Help Ease Epileptic Seizures – PR Web

"We are committed in adopting technology that is at the forefront of surgical treatments for epilepsy. The use of the robot will help the Memorial Neuroscience Institute to provide the cutting edge care to our patients.

HOLLYWOOD, Fla. (PRWEB) February 26, 2020

The epilepsy team at Memorial Neuroscience Institute successfully completed its first use of a minimally-invasive, robotic device that helps pinpoint the origin of epileptic seizures on a patient.

The device, now in full use at Memorial Regional Hospital, is called a Robotized Surgical Assistant, or ROSA. With assistance from the robot, neurosurgeons only need to make small, precise incisions in the scalp and skull to place electrodes deep in the brain and investigate where seizures are triggered.

The robot also improves accuracy, safety and can significantly reduce total surgery time, said Tarek Zakaria, MD, Medical Director for the Adult Neurology Program and Epilepsy Program.

By using the new technology, more data will be available to the epilepsy team to offer patients more advanced treatment options and help them to achieve their dreams to be seizure free, Zakaria said.

"We are committed in adopting technology that is at the forefront of surgical treatments for epilepsy," Zakaria said. The use of the robot will help the Memorial Neuroscience Institute to provide the cutting edge care to our patients.

When medication is not enough to control seizures, neurosurgeons like Christopher DeMassi, MD and Daxa Patel, MD may take a surgical approach. That includes altering or removing brain tissue at the location where a patient's seizures begin. However, they can only do so if they can first zero in exactly where that origin is. This is where Rosa can assist.

Recently, they performed the two-part procedure on a 24-year-old female patient, who began having epileptic seizures at age eight and had exhausted all available medications.

The procedure, called robot-assisted stereoelectroencephalography (SEEG), was performed as part of the services offered by the Memorial Neuroscience Institute Comprehensive Epilepsy Center.

Our goal is to always bring in the latest innovative technologies to achieve the best possible outcome for our patients, DeMassi said. This is just the latest advancement available to the South Florida community and keeps us at the front of epilepsy care.

Surgeons used ROSA and a 3-D reconstruction of the patients brain to guide them where to surgically implant electrodes without having to remove sections of her skull. DeMassi and Patel then used the robot's arm to make two- or three-millimeter holes in the scalp through which the electrode wires were passed.

With the electrodes in place, Zakaria and his team were later able to see part of the patient's brain light up on a computer monitor as a seizure began, essentially flagging the point of origin.

Memorial Neuroscience Institute is proud to offer the most technologically advanced and comprehensive services for our patients and the community, said Haroula Protopapadakis Nordem, FACHE, Associate Administrator at Memorial Regional Hospital.

The addition of the ROSA to our program will allow our surgeons to deliver more precise results in a less invasive manner and allow our physicians to treat patients who otherwise might not have had a feasible treatment option, she said.

Memorials epilepsy center is accredited by the National Association of Epilepsy Centers (NAEC) as a Level 4 program, a designation for programs offering the highest level of comprehensive and specialized care.

Memorial Regional Hospital in Hollywood, Fla., is one of the largest hospitals in Florida and is a facility of Memorial Healthcare System, one of the largest healthcare systems in Florida. Its wide scope of medical services and programs includes Memorial Cancer Institute, Breast Cancer Center, Cardiac and Vascular Institute, Neuroscience Center, Comprehensive Weight-Loss Surgery Program, Family Birthplace, Center for Behavioral Health, Sickle Cell Day Hospital, Womens Services, Fitness and Rehabilitation Center, and a level I Trauma Center. For more information, visit memorialregional.com.

Share article on social media or email:

Read this article:
Memorial Neuroscience Institute Performs Its First Robotic Brain Surgery to Help Ease Epileptic Seizures - PR Web